Negative growth effects of ciglitazone on kidney interstitial fibroblasts: Role of PPAR-γ

Kidney and Blood Pressure Research

Volumn 26, Issue 1, 2003, Pages 2-9

  Parameswaran, Narayanan ^a   Hall, Carolyn S ^a   Bomberger, Jennifer M ^a   Sparks, Harvey V ^a   Jump, Donald B ^a   Spielman, William S ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Ciglitazone; Mesangial cells; NRK 49F; PPAR ; Thiazolidinedione

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CHLORAMPHENICOL ACETYLTRANSFERASE; CIGLITAZONE; DNA FRAGMENT; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THYMIDINE KINASE; TROGLITAZONE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ASSAY; CELL CULTURE; CELL GROWTH; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FIBROBLAST; GENE ACTIVATION; GENETIC TRANSFECTION; GLOMERULUS; KIDNEY INTERSTITIUM; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAT; REPORTER GENE;

ANIMALS; APOPTOSIS; CASPASES; CELL DIVISION; CELLS, CULTURED; FIBROBLASTS; GLOMERULAR MESANGIUM; HYPOGLYCEMIC AGENTS; LIGANDS; MICE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0037262092     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069764     Document Type: Article

References (35)

1. Lebovitz HE, Banerji MA: Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001;56:265-294.
2. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-1669.
3. Mudaliar S, Henry RR: New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu Rev Med 2001;52:239-257.
4. Murphy GJ, Holder JC: PPAR-γ agonists: Therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 2000;21:469-474.
5. Guan Y, Breyer MD: Peroxisome proliferator-activated receptors: Novel therapeutic targets in renal disease. Kidney Int 2001;60:14-30.
6. Fujita T, Sugiyama Y, Taketomi S, et al: Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 1983;32:804-810.
7. Diani AR, Peterson T, Sawada G, et al: Ciglitazone, a new hypoglycemic agent. 5. Effect on renal lesions in C57BL/KsJ-db/db mice. Nephron 1986;42:72-77.
8. Buckingham RE, Al-Barazanji KA, Toseland CD, et al: Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998;47:1326-1334.
9. Yoshimoto T, Naruse M, Nishikawa M, et al: Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 1997;272:E989-E996.
10. Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa R: Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000;49:1022-1032.
11. Fujiwara K, Hayashi K, Ozawa Y, Tokuyama H, Nakamura A, Saruta T: Renal protective effect of troglitazone in Wistar fatty rats. Metabolism 2000;49:1361-1364.
12. McCarthy KJ, Routh RE, Shaw W, Walsh K, Welbourne TC, Johnson JH: Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 2000;58:2341-2350.
13. Imano E, Kanda T, Nakatani Y, et al: Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998;21:2135-2139.
14. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB: Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001;59:1899-1910.
15. Rovin BH, Wilmer WA, Lu L, et al: 15-Deoxy-Δ 12,14-prostaglandin J2 regulates mesangial cell proliferation and death. Kidney Int 2002;61:1293-1302.
16. Yang T, Michele DE, Park J, et al: Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol 1999;277:F966-F973.
17. Ren B, Thelen A, Jump DB: Peroxisome proliferator-activated receptor-α inhibits hepatic S14 gene transcription. Evidence against the peroxisome proliferator-activated receptor-α as the mediator of polyunsaturated fatty acid regulation of s14 gene transcription. J Biol Chem 1996;271:17167-17173.
18. Clayton A, Thomas J, Thomas GJ, Davies M, Steadman R: Cell surface heparan sulfate proteoglycans control the response of renal interstitial fibroblasts to fibroblast growth factor-2. Kidney Int 2001;59:2084-2094.
19. Gupta RA, Tan J, Krause WF, et al: Prostacyclin-mediated activation of peroxisome proliferator-activated receptor-δ in colorectal cancer. Proc Natl Acad Sci USA 2000:97:13275-13280.
20. Klahr S, Schreiner G, Ischikawa I: The progression of renal disease. N Engl J Med 1988;318:1657-1666.
21. Becker GJ, Hewitson TD: The role of tubulointerstitial injury in chronic renal failure. Curr Opin Nephrol Hypertens 2000;9:133-138.
22. O'Donnell MP: Renal tubulointerstitial fibrosis. New thoughts on its development and progression. Postgrad Med 2000;108:159-162, 165, 171-172.
23. 1) expresses in rat mesangial cells and PPAR-γ agonists modulate its differentiation. Biochim Biophys Acta 2000;1497:148-154.
24. Nicholas SB, Kawano Y, Wakino S, Collins AR, Hsueh WA: Expression and function of peroxisome proliferator-activated receptor-γ in mesangial cells. Hypertension 2001;37:722-727.
25. Peters JM, Lee SS, Li W, et al: Growth, adipose, brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor-β(δ). Mol Cell Biol 2000;20:5119-5128.
26. Saluja I, Granneman JG, Skoff RP: PPAR-δ agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 2001;33:191-204.
27. Hansen JB, Zhang H, Rasmussen TH, Petersen RK, Flindt EN, Kristiansen K: Peroxisome proliferator-activated receptor-δ-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. J Biol Chem 2001;276:3175-3182.
28. Rovin BH, Lu L, Cosio A: Cyclopentenone prostaglandins inhibit cytokine-induced NFκB activation and chemokine production by human mesangial cells. J Am Soc Nephrol 2001;12:1659-1667.
29. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA: Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor-γ and mediated by inhibition of translation initiation. Cancer Res 2001;61:6213-6218.
30. Davies GF, Khandelwal RL, Wu L, Juurlink BH, Roesler WJ: Inhibition of phosphoenolpyruvate carboxykinase gene expression by troglitazone: A peroxisome proliferator-activated receptor-γ-independent, antioxidant-related mechanism. Biochem Pharmacol 2001;62:1071-1079.
31. Ishizuka T, Itaya S, Wada H, et al: Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes 1998;47:1494-1500.
32. Pershadsingh HA, Szollosi J, Benson S, Hyun WC, Feuerstein BG, Kurtz TW: Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension 1993;21:1020-1023.
33. Wu SN, Ho LL, Li HF, Chiang HT: Regulation of Ca(2+)-activated K+ currents by ciglitazone in rat pituitary GH3 cells. J Investig Med 2000;48:259-269.
34. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM: PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001;7:48-52.
35. Wang M, Wise SC, Leff T, Su TZ: Troglita-zone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-γ. Diabetes 1999;48:254-260.